Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

November 29, 2021 09:00 ET | Source: CohBar, Inc.

CohBar’s CEO to Participate in Upcoming BIO Webinar

MENLO PARK, Calif., Nov. 29, 2021 (GLOBE NEWSWIRE) -- CohBar, Inc. (NASDAQ: CWBR), a clinical stage biotechnology company developing mitochondria based therapeutics to treat chronic diseases and...
November 15, 2021 16:02 ET | Source: CohBar, Inc.

CohBar Reports Third Quarter 2021 Financial Results and Provides Business Update

Company to host conference call at 5:00 p.m. ET MENLO PARK, Calif., Nov. 15, 2021 (GLOBE NEWSWIRE) -- CohBar, Inc. (NASDAQ: CWBR), a clinical stage biotechnology company developing mitochondria...
November 01, 2021 09:00 ET | Source: CohBar, Inc.

CohBar to Announce 2021 Third Quarter Financial Results and Provide Business Update on November 15, 2021

MENLO PARK, Calif., Nov. 01, 2021 (GLOBE NEWSWIRE) -- CohBar, Inc. (NASDAQ: CWBR), a clinical stage biotechnology company developing mitochondria based therapeutics to treat chronic diseases and...
October 28, 2021 08:45 ET | Source: CohBar, Inc.

CohBar Announces Pricing of $15.0 Million Public Offering of Common Stock and Warrants

MENLO PARK, Calif., Oct. 28, 2021 (GLOBE NEWSWIRE) -- CohBar, Inc. (NASDAQ: CWBR) (the “Company”), a clinical stage biotechnology company developing mitochondria based therapeutics to treat chronic...
October 27, 2021 16:01 ET | Source: CohBar, Inc.

CohBar Announces Proposed Public Offering of Common Stock and Warrants

MENLO PARK, Calif., Oct. 27, 2021 (GLOBE NEWSWIRE) -- CohBar, Inc. (NASDAQ: CWBR) (the “Company”), a clinical stage biotechnology company developing mitochondria based therapeutics to treat chronic...
October 13, 2021 09:00 ET | Source: CohBar, Inc.

CohBar Announces CB4211 Phase 1a/1b Results Selected for Late Breaker Presentation at The Liver Meeting® 2021

MENLO PARK, Calif., Oct. 13, 2021 (GLOBE NEWSWIRE) -- CohBar, Inc. (NASDAQ: CWBR), a clinical stage biotechnology company developing mitochondria based therapeutics to treat chronic diseases and...
October 05, 2021 09:00 ET | Source: CohBar, Inc.

CohBar to Present at H.C. Wainwright 5th Annual NASH Investor Conference

MENLO PARK, Calif., Oct. 05, 2021 (GLOBE NEWSWIRE) -- CohBar, Inc. (NASDAQ: CWBR), a clinical stage biotechnology company developing mitochondria based therapeutics to treat chronic diseases and...
September 15, 2021 09:00 ET | Source: CohBar, Inc.

CohBar Appoints Joanne Yun, Ph.D. to Its Board of Directors

MENLO PARK, Calif., Sept. 15, 2021 (GLOBE NEWSWIRE) -- CohBar, Inc. (NASDAQ: CWBR), a clinical stage biotechnology company developing mitochondria based therapeutics to treat chronic diseases and...
September 08, 2021 09:00 ET | Source: CohBar, Inc.

CohBar Granted U.S. Patent Covering CB4211 Compositions and Use for Treating Nonalcoholic Steatohepatitis (NASH)

MENLO PARK, Calif., Sept. 08, 2021 (GLOBE NEWSWIRE) -- CohBar, Inc. (NASDAQ: CWBR), a clinical stage biotechnology company developing mitochondria based therapeutics to treat chronic diseases and...
September 02, 2021 16:05 ET | Source: CohBar, Inc.

CohBar to Present at Upcoming Investor Conferences

MENLO PARK, Calif., Sept. 02, 2021 (GLOBE NEWSWIRE) -- CohBar, Inc. (NASDAQ: CWBR), a clinical stage biotechnology company developing mitochondria based therapeutics to treat chronic diseases and...